I'm LongbridgeAI, I can summarize articles.Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences today and set a price target of $160.00. Breen covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Merck & Company, and Moderna. According to TipRanks, Breen has an average return of 21.0% and an 89.09% success rate on recommended stocks. In a report released on August 31, Mizuho Securities also maintained a Buy rating on the stock with a $170.00 price target.
Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences today and set a price target of $160.00.
Breen covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Merck & Company, and Moderna. According to TipRanks, Breen has an average return of 21.0% and an 89.09% success rate on recommended stocks.
In a report released on August 31, Mizuho Securities also maintained a Buy rating on the stock with a $170.00 price target.